Compare SoFi Technologies Inc (SOFI) vs TransMedics Group Inc (TMDX) Price & Performance

SOFI Technologies trades at $15.61, down 0.32% with a bearish technical outlook. The stock shows strong fundamental progress with revenue growth from $1.6B in 2022 to $3.6B in 2025 and consistent earnings beats. Analyst consensus is mixed with a $21.58 price target representing 38% upside potential. Recent news highlights stablecoin initiatives and record loan originations despite stock underperformance.

SOFI presents a growth opportunity with expanding revenue and profitability, though execution risks and rate sensitivity remain concerns. The valuation at 31.86 P/E appears reasonable for growth trajectory, but negative operating cash flows and competitive pressures warrant caution. Near-term catalyst includes Q3 earnings on October 27, 2026.

TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.

The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.